Clinical Trial: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07367178) titled 'Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer' on Jan. 16.

Brief Summary: The SATROPIN study is an international, multicenter, open-label, single-arm, phase II clinical trial to assess whether the use of prophylactic administration of atropine may prevent diarrhea in participants with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) or hormone receptor-positive/HER2-negative (HR(+)/HER2-) treated with sacituzumab govitecan.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Breast Cancer Advanced HR+/HER2- Breast C...